addition, mutation spectrum in UTUC were also different depending on the anatomical location; Most of the RAS pathway mutations were found in renal pelvis (p¼0.0013) while KMT2D mutations were observed more frequently in ureter (p<0.0001). In the analysis of normal epithelia, some epithelia and primary tumors harbored shared mutations as well as their private ones, indicating that clonal precancerous area expands in normal epithelia. By contrast, in other epithelia, we also found driver gene mutations that were not shared by primary tumors, suggesting the presence of a mutagenic field effect on urothelial multiple occurence. We also detected mutations in urine sediments identical to primary tumors with similar allele frequencies, suggesting that sequencing urine may be useful for disease monitoring.
INTRODUCTION AND OBJECTIVES: To investigate the prognostic value of PD-1 and PD-L1 expression in patients with highgrade upper tract urothelial carcinoma (UTUC).
METHODS: Tissue microarrays were created using 448 patients from the International UTUC collaboration who underwent extirpative surgery for high-grade UTUC and stained for PD-1 (antibody (AB): NAT105, diluted 1:250 from Ventana) and PD-L1 (AB: E1L3NÓ prediluted from Cell Signaling). PD-1 and PD-L1 expression was assessed in a semi-quantitative fashion and any percentage of staining of the tumor cells (PD-L1) and tumor-infiltrating lymphocytes (PD-1) was considered positive. Univariate (UVA) and multivariate analyses (MVA) were performed to assess independent prognosticators of oncological outcomes. No funding was received.
RESULTS: Median age of the cohort was 69.2 years and 56.5% of patients were male. PD-L1 and PD-1 were positive in 24.1% and 37.5% of patients. PD-L1 positivity was associated with favorable pathological stage, where as PD-1 positivity was significantly associated with pelvicalyceal location, lymph node metastases, non-organ confined disease, presence of lymphovascular invasion, sessile architecture, necrosis, concomitant CIS, and history of non-muscle invasive bladder cancer. PD-L1 positivity was not significantly associated with survival outcomes. In Cox regression UVA, PD-1 positivity was associated with worse recurrence-free survival (RFS) (HR 1.5 (95%CI 1.08-2.14, p¼0.016)), cancer-specific survival (CSS) (HR 1.5 (95%CI 1.07-2.19, p¼0.021)), and overall survival (OS) (HR 1.5 (95%CI 1.10-1.97, p¼0.009)) (see figure for KM curves). However in MVA, PD-1 positivity was not found to be an independent predictor of RFS, CSS or OS.
CONCLUSIONS: PD-1 positivity of tumor-infiltrating lymphocytes was associated with adverse pathological criteria and was a significant prognosticator for RFS, CSS and OS on UVA in patients treated with extirpative surgery for high-grade UTUC in a large, multiinstitutional cohort. In MVA, the independent prognostic value of PD-1 was not confirmed. PD-L1 positivity was associated with lower tumor stage, but not with other pathological characteristics or survival outcomes.
Source of Funding: none

MP71-04 GATA3 IMMUNOHISTOCHEMISTRY IN UROTHELIAL CARCINOMA OF THE UPPER URINARY TRACT AS A UROTHELIAL MARKER AS WELL AS A PROGNOSTICATOR
Satoshi Inoue*, Rochester, NY; Kazutoshi Fujita, Suita, Japan; Hiroki Ide, Tokyo, Japan; Seiji Yamaguchi, Hiroaki Fushimi, Osaka, Japan; George Netto, Birmingham, AL; Norio Nonomura, Suita, Japan; Hiroshi Miyamoto, Rochester, NY INTRODUCTION AND OBJECTIVES: A transcription factor, GATA3, has been one of the most useful urothelial markers in diagnostic surgical pathology practice. However, previous studies have assessed the utility of GATA3 immunohistochemistry often in bladder specimens. Moreover, the prognostic significance of GATA3 expression in upper urinary tract urothelial carcinomas (UUTUCs) has not been fully investigated. Meanwhile, using cell line and animal models, we have demonstrated that GATA3 functions as a tumor suppressor for Vol. 197, No. 4S, Supplement, Monday, May 15, 2017 THE JOURNAL OF UROLOGY â e945
urothelial cancer. The current study aims to determine the expression status of GATA3 in UUTUC and its prognostic significance. METHODS: We immunohistochemically stained for GATA3 in the tissue microarrays consisting of 99 UUTUC samples and paired non-neoplastic urothelium from each case. We then evaluated the associations between GATA3 expression and clinicopathologic features available for our patient cohort.
RESULTS: GATA3 was positive in 51 [52%; 32 (32%) weak, 11 (11%) moderate, 8 (8%) strong] of 99 UUTUCs, which was significantly lower than in benign urothelium [79 (96%) of 82; 33 (40%) weak, 35 (43%) moderate, 11 (13%) strong] (P < 0.001). Ten (67%) of 15 lowgrade versus 41 (48%) of 84 high-grade UUTUCs (P ¼ 0.266) and 20 (54%) of 37 non-muscle-invasive versus 31 (50%) of 62 muscle-invasive UUTUCs (P ¼ 0.836) were immunoreactive for GATA3. There were also no statistically significant associations between GATA3 expression and pN status, distant metastasis, gender of the patients, or the side of UUTUC. However, the rate of GATA3 positivity was significantly higher (P ¼ 0.004) in ureteral tumors (66%) than in renal pelvic tumors (36%). Kaplan-Meier and log-rank tests revealed that GATA3 negativity significantly correlated with lower recurrence-free survival (P ¼ 0.040 for all cases; P ¼ 0.030 for muscle-invasive tumors) and cancer-specific survival (P ¼ 0.007 for all cases; P ¼ 0.012 for muscle-invasive tumors) rates. Multivariate analysis further identified strong correlations of GATA3 expression with cancer-specific mortality of all cases [hazard ratio (HR) ¼ 0.399, 95% confidence interval (CI) ¼ 0.179-0.890, P ¼ 0.025] or muscle-invasive tumors (HR ¼ 0.374, 95% CI ¼ 0.169-0.831, P ¼ 0.016).
CONCLUSIONS: Compared with non-neoplastic urothelium, a significant decrease in the expression of GATA3 in UUTUC was seen. Of note was that GATA3 was immunohistochemically detected only in roughly half of high-grade and/or muscle-invasive UUTUCs. In addition, loss of GATA3 expression was found to be an independent predictor of poor patient outcomes.
Source of Funding: None
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